

## Erratum

---

The affiliation of Daiki Ogawara, first author of the paper ‘Phase I/II study of amrubicin and nedaplatin in patients with untreated, advanced, non-small cell lung cancer‘ [Chemotherapy 2014;60:180–184, DOI: 10.1159/000371870], should read:

Second Department of Internal Medicine, Nagasaki University Hospital, and Unit of Molecular Microbiology and Immunology, Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.